These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039 [TBL] [Abstract][Full Text] [Related]
7. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Mickisch GH Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059 [TBL] [Abstract][Full Text] [Related]
10. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399 [TBL] [Abstract][Full Text] [Related]
13. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R; Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750 [TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for advanced renal cell carcinoma. Coppin C; Le L; Porzsolt F; Wilt T Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006017. PubMed ID: 18425931 [TBL] [Abstract][Full Text] [Related]
15. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
16. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901 [TBL] [Abstract][Full Text] [Related]
17. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034 [TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402 [TBL] [Abstract][Full Text] [Related]
20. Chemo-immunotherapy in RCC: the end of a story. Escudier B Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385 [No Abstract] [Full Text] [Related] [Next] [New Search]